Brind.
  1. NRx Pharmaceuticals achieved VAI status in Vai and is now seeking clearance for its KetAFree drug launch with the FDA.

NRx Pharmaceuticals is undergoing a first-cycle review of an ANDA for ketamine, noting its strategic importance for the U.S. military and VA.

2 reports, 2 independent Updated Aug 10
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

NRx Pharmaceuticals is undergoing a first-cycle review of an ANDA for ketamine, noting its strategic importance for the U.S. military and VA.

Who's involved

What this event is mainly about
FDA

Keep exploring

Part of

NRx Pharmaceuticals achieved VAI status in Vai and is now seeking clearance for its KetAFree drug launch with the FDA. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped